Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smart glucose monitor improve diabetes care? new trial aims to find out.

NCT ID NCT05633628

Disease control Sponsor: Sophiahemmet University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a continuous glucose monitor (CGM) for short periods, combined with personalized feedback, helps adults with type 2 diabetes control their blood sugar better than standard finger-prick testing. About 400 participants will be randomly assigned to either periodic CGM or usual self-monitoring. The main goal is to see if HbA1c levels improve over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
continuous glucose monitoring (CGM) device
What this could lead to
If successful, this could show that periodic CGM with personalized feedback helps people with type 2 diabetes better manage their blood sugar levels.
What could go wrong
This is a behavioral intervention study, not a drug trial, so the effect may be modest. Results depend on patient engagement and may not apply to everyone with type 2 diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-80 years * Type 2 diabetes with a duration of \> 6 months * HbA1c 45-70 mmol/mol * Have a smartphone * Experience of self-monitoring of blood glucose prior to the study start Exclusion Criteria: * Prandial insulin * Pregnancy or planning pregnancy during the study * Breastfeeding * Renal disease with estimated glomerular filtration rate (eGFR) \<45 mL/ min/1.73 m2 * Active malignancy or under investigation for malignancy * Severe visual impairment * Severe skin allergy that inhibits the use of a continuous glucose monitoring device * Glucocorticoids (systemic) * Planned or currently using weight reduction medications, programs, or surgery * Cognitively or psychologically unable to participate and read instructions * Enrolled in other clinical trials * Eating disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sophiahemmet University

    RECRUITING

    Stockholm, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.